Biogen Idec and Abbott Announce Enrollment of First Patient in Global Phase III Study of Daclizumab for Relapse Remitting Multiple Sclerosis Abbot, 24 May 2010 Accessed on 3 Dec 2011 from http://www.abbott.com/news-media/press-releases/Press_Release_0863.htm. CommentRecommendBookmarkWatch